Zampilimab (UCB-7858) is a humanised monoclonal antibody targeting TGM2, which binds to and inhibits the cross-linking transamidase activity of TG2, and is used to improve renal fibrosis.

Methods:
A renal tubular interstitial fibrosis model was established by treating primary human RPTEC cells with TGF-β1. Extracellular TG2 activity was measured using a biotin-cadaverine incorporation assay, and the inhibitory effect of Zampilimab was evaluated across four independent experiments.
Results:
Zampilimab significantly inhibited extracellular TG2 activity and reduced ECM accumulation, with an IC₅₀ of 119 nM, indicating strong anti-fibrotic potential. [1]

Methods:
In a cynomolgus monkey model of chronic kidney disease induced by unilateral ureteral obstruction (UUO), Zampilimab was administered intravenously at doses of 10–50 mg/kg once weekly for 21 days to evaluate its effects on in situ TG2 activity and renal fibrosis.
Results:
Zampilimab treatment effectively reduced in situ TG2 activity in kidney tissue and alleviated renal fibrosis.